First patient receives TCR-T cell therapy targeting mutant KRAS pancreatic cancer
Discover the latest breakthroughs in cancer cell therapies in this edition of RegMedNet’s Cell Therapy Weekly, including news that the first patient has been dosed with a novel T cell receptor-modified T cell therapy targeting KRAS G12V mutations in an aggressive form of pancreatic cancer and key updates in the progress made in developing programmable T-cell and macrophage therapies for solid tumors.